Patients from 22+ countriesPlan your visit →
lutetium-therapy
Comparing Options · 26 Aug 2026

Can You Get Lu-177 PSMA Without Chemo First?

In March 2025, the FDA expanded its approval of lutetium Lu 177 vipivotide tetraxetan to cover mCRPC patients who have not yet had taxane chemotherapy. This article explains what changed, who now qualifies, and how sequencing decisions are shifting for men with PSMA-positive mCRPC.

Editorial oversight by Arpan Talwar·Founder, Art of Healing CancerUpdated 26 Aug 2026
Can You Get Lu-177 PSMA Without Chemo First?

If you have metastatic castration-resistant prostate cancer (mCRPC) and have heard about Lu-177 PSMA therapy, you may have one pressing question: do you have to go through chemotherapy first? For years, the answer was yes. But in March 2025, the U.S. Food and Drug Administration expanded its approval of lutetium Lu 177 vipivotide tetraxetan - the drug sold as Pluvicto - to include some men who have not yet had taxane-based chemotherapy. This article is for men with PSMA-positive mCRPC, and for their families, who want to understand what that shift means and whether it changes their treatment options.

Why treatment sequencing matters in mCRPC

mCRPC means prostate cancer that has spread to other parts of the body - most often bones and lymph nodes - and continues to grow despite testosterone-lowering hormone therapy. When cancer reaches this stage, your oncology team will discuss which treatment to use next and in what order. That discussion is called sequencing.

Sequencing matters for real reasons. Some treatments work better at a specific point in the disease. Some therapies can cause resistance that makes later options less effective. And some treatments have access requirements - you need to have had certain prior therapies before you can receive them. Until recently, Lu-177 PSMA therapy was in that last category. You needed chemotherapy first. That requirement has now changed for some patients.

What the original approval required

When the FDA first approved lutetium Lu 177 vipivotide tetraxetan in March 2022, the label was specific. To qualify, patients had to have already received both of the following:

  • at least one androgen receptor pathway inhibitor (ARPI) - drugs such as enzalutamide or abiraterone that block testosterone from fueling cancer growth
  • one or two taxane-based chemotherapy regimens, such as docetaxel or cabazitaxel

That requirement came from the VISION trial, a large international phase 3 study. VISION enrolled 831 patients with heavily pre-treated mCRPC and compared adding lutetium Lu 177 vipivotide tetraxetan to standard of care against standard of care alone. According to the clinical review of Pluvicto on NCBI Bookshelf, the trial showed statistically significant improvements in overall survival, radiographic progression-free survival, and time to first symptomatic skeletal event. Those are meaningful results - but because VISION only enrolled patients who had already completed chemotherapy, the approval was limited to that group.

What changed in March 2025

On March 28, 2025, the FDA expanded the approved use of this therapy. According to the FDA announcement, lutetium Lu 177 vipivotide tetraxetan is now approved for adults with PSMA-positive mCRPC who have received ARPI therapy and are considered appropriate to delay taxane-based chemotherapy. In plain language: if you have tried one ARPI and your oncologist believes it is reasonable to hold off on chemotherapy for now, you may be eligible for Lu-177 PSMA therapy earlier in your treatment path.

The American Society of Clinical Oncology noted, in its coverage of the expansion, that this expanded approval gives patients and oncologists a new option at an earlier decision point - specifically for men in whom a taxane delay is clinically appropriate.

What the PSMAfore trial found

The March 2025 expansion was based on the PSMAfore trial. PSMAfore was a phase 3, randomized, open-label study that enrolled 468 patients with PSMA-positive mCRPC who had progressed on one ARPI and had not yet received taxane chemotherapy. Patients were divided 1:1 into two groups: one received lutetium Lu 177 vipivotide tetraxetan once every six weeks for up to six cycles; the other switched to a different ARPI - either abiraterone or enzalutamide.

According to the PSMAfore trial publication in PubMed Central, the lutetium arm showed a statistically significant improvement in radiographic progression-free survival compared with switching ARPI. The median radiographic progression-free survival in the ARPI-switch group was 5.59 months at the third data analysis point. The Prostate Cancer Foundation, reviewing the expanded approval, noted that Lu-177 PSMA therapy demonstrated better disease control and a more favorable safety profile than changing to a second ARPI in this pre-chemo setting.

How does the pre-chemo pathway compare with the post-chemo pathway for Lu-177 PSMA?

Comparison of Lu-177 PSMA therapy sequencing in mCRPC: pre-chemotherapy pathway (PSMAfore) vs post-chemotherapy pathway (VISION)
Comparison Lu-177 PSMA (pre-chemo pathway) Lu-177 PSMA (post-chemo pathway)
Prior treatment required At least one ARPI; no taxane required At least one ARPI plus one or two taxane regimens
Trial that supports it PSMAfore (phase 3, 468 patients) VISION (phase 3, 831 patients)
FDA approval date March 2025 March 2022
Key eligibility condition PSMA-PET positive; oncologist considers taxane delay appropriate PSMA-PET positive; prior taxane therapy confirmed
Trial comparator Switch to a second ARPI Best standard of care
Dosing schedule 7.4 GBq IV every 6 weeks, up to 6 cycles 7.4 GBq IV every 6 weeks, up to 6 cycles

Sources: PSMAfore trial data from PubMed Central; VISION trial data from NCBI Bookshelf; FDA approval dates from FDA.gov.

Both pathways use the same drug at the same dose. The meaningful difference is timing. Under the pre-chemo pathway, a man who has progressed on one ARPI may access Lu-177 PSMA therapy before going through docetaxel or cabazitaxel - as long as his oncologist considers a chemotherapy delay clinically appropriate. Under the original post-chemo pathway, taxane chemotherapy must already have been completed. The treatment schedule is the same in both settings.

Who qualifies under the pre-chemo pathway?

Based on the PSMAfore trial criteria and the FDA updated label, a patient generally needs to meet all of the following:

  • A confirmed diagnosis of mCRPC - prostate cancer that has spread beyond the prostate and continues to grow despite hormone therapy
  • PSMA expression confirmed on a PSMA-PET scan (see the next section)
  • Prior treatment with at least one ARPI, with disease progression during or after that treatment
  • An oncologist's judgment that it is appropriate to delay taxane-based chemotherapy given the patient's current situation

Being fit enough for chemotherapy but choosing to delay it is different from being medically unable to receive it. Both situations can potentially open this pathway. Your oncologist will weigh your overall health, your performance status, how fast your disease is moving, and your own priorities when making that call.

The PSMA-PET scan: the gateway to eligibility

A positive PSMA-PET scan is required for both pathways. This scan uses a radiotracer - most commonly gallium-68 PSMA-11 (Locametz) or fluorine-18 piflufolastat (Pylarify) - to show whether cancer cells in your body express the PSMA protein on their surface. Lutetium Lu 177 vipivotide tetraxetan works by attaching to that same PSMA protein and delivering targeted radiation directly to those cells. If your cancer does not express PSMA strongly, the therapy may not have a target to bind to.

The VISION trial required that patients have at least one PSMA-positive lesion on their scan and no significant PSMA-negative lesions - meaning no tumors that show little or no PSMA uptake. If you have a mix of PSMA-positive and PSMA-negative sites, your eligibility is less straightforward and will need careful individual review.

For a detailed explanation of how your scan report translates to an eligibility assessment, read our guide on what your PSMA-PET results mean for Lu-177 eligibility.

What "appropriate to delay chemotherapy" really means

This phrase is a clinical judgment, not a fixed rule. It does not mean chemotherapy is ruled out permanently. It means your oncologist believes there is a reasonable basis - given your age, health, disease pace, and your own preferences - for trying Lu-177 PSMA therapy before moving to a taxane.

Factors that may make delay more reasonable include: older age or other health conditions that increase chemotherapy risk, disease progressing at a slower pace, or a strong preference to avoid the side-effect profile of taxane-based treatment. Factors that may make delay less appropriate include: rapidly rising PSA, widespread symptomatic bone disease, or soft-tissue metastases in organs such as the liver or lungs that need fast control.

Talk carefully with your oncology team about this. If you would like a second opinion before deciding on a plan, ask whether Lu-177 fits your case through Art of Healing Cancer. Their oncology and nuclear-medicine specialists can review your scans, your prior treatment history, and your current staging to help you reach a clearer picture.

Does getting Lu-177 PSMA early rule out chemotherapy later?

Not necessarily. For many patients, Lu-177 PSMA therapy may become one step in a longer sequence rather than a permanent replacement for chemotherapy. If disease progresses after a course of Lu-177 PSMA therapy, taxane-based chemotherapy may still be considered as a next step, alongside other agents that may be appropriate for your individual case.

Research into the best sequencing of all available mCRPC therapies - ARPIs, Lu-177 PSMA, taxanes, PARP inhibitors, and others - is ongoing, and the evidence continues to develop. For now, the key point is that choosing Lu-177 PSMA therapy before chemotherapy does not prevent using chemotherapy later.

If you want to understand in detail how the two approaches compare on tolerability, outcomes, and access, our article on Lu-177 PSMA vs taxane chemotherapy after hormone failure walks through the evidence on both sides.

What if you do not qualify?

Some patients with mCRPC will not meet the criteria for Lu-177 PSMA therapy. PSMA-negative disease is the most common reason: if the cancer cells do not express the PSMA protein in sufficient quantity, the therapy cannot bind to them and is unlikely to produce a meaningful response. Other factors that may affect eligibility include significantly reduced kidney function, very low blood counts, or certain liver conditions.

If you are told you do not qualify, it is worth asking whether a second opinion on that assessment is available. Eligibility criteria can be interpreted in slightly different ways across centers, and an expert review of your scans and lab results may provide a fuller picture of your options. Our article on Lu-177 PSMA resistance and next steps for mCRPC covers what may still be possible when this therapy is not an option or has stopped working.

Bone health and supportive care during hormone therapy

Men with mCRPC are almost always on some form of androgen deprivation therapy (ADT), which lowers testosterone over time. One effect of long-term ADT is a gradual reduction in bone density - this matters more when bone metastases are already present. Many patients ask what they can do between cycles or alongside treatment to support their bones. Bone health supplements like the Joint and Bone range may help. Always tell your oncologist or care team about any supplement you are considering, since some can interact with cancer medications or affect lab values.

When to talk to your doctor

If your prostate cancer has progressed on an ARPI and you have not yet received taxane chemotherapy, now is the time to ask your oncologist whether Lu-177 PSMA therapy might be appropriate before chemotherapy. Specifically, ask whether a PSMA-PET scan has been done or is planned, and whether the 2025 expanded FDA approval applies to your situation.

If you are looking for an eligibility review or want to explore treatment options - including access to Lu-177 PSMA therapy abroad - use the Lutetium Therapy contact form to share your scan results and case summary for review. If Lu-177 PSMA therapy is not right for your situation, the team can also provide a second opinion on what alternatives may be available.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.

Frequently asked questions

Does the FDA now allow Lu-177 PSMA therapy before chemotherapy?

Yes. In March 2025, the FDA expanded the approval of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) to include adults with PSMA-positive mCRPC who have received an ARPI and whose oncologist considers taxane chemotherapy appropriate to delay. This is in addition to the original 2022 approval, which required prior taxane chemotherapy. Both pathways remain valid; the right one for you depends on your treatment history and your oncologist's clinical assessment.

What is the PSMAfore trial and what did it show?

PSMAfore was a phase 3 clinical trial of 468 patients with PSMA-positive mCRPC who had progressed on one ARPI and had not yet received taxane chemotherapy. It compared lutetium Lu 177 vipivotide tetraxetan against switching to a second ARPI. The trial showed that Lu-177 PSMA therapy significantly improved radiographic progression-free survival compared with an ARPI change. In the ARPI-switch group, the median radiographic progression-free survival was 5.59 months at the third data analysis point. These results supported the FDA's decision to expand the approval in March 2025.

What does 'appropriate to delay chemotherapy' mean in practice?

It is a clinical judgment your oncologist makes based on your overall health, the pace of your disease, your other medical conditions, and your own preferences. It does not mean chemotherapy is ruled out permanently. It means that, in your oncologist's view, there is a reasonable basis for trying Lu-177 PSMA therapy first before moving to a taxane. Patients who are fit enough for chemotherapy but prefer to delay it, and patients who have health conditions that make chemotherapy riskier, may both fall into this category. Your oncologist will assess your individual situation.

Do I need a PSMA-PET scan before Lu-177 PSMA therapy?

Yes. A positive PSMA-PET scan is required for both the pre-chemo and post-chemo pathways. The scan checks whether your cancer cells express the PSMA protein, which the therapy needs to bind to in order to work. If the cancer does not express PSMA strongly, or if there are significant PSMA-negative tumors alongside PSMA-positive ones, your eligibility may be affected. Your scan report is one of the most important documents in any eligibility review.

Can I still get Lu-177 PSMA therapy if I have already had chemotherapy?

Yes. The original 2022 FDA approval still covers patients who have received at least one ARPI and one or two taxane-based chemotherapy regimens. The 2025 expansion adds a new pre-chemo pathway - it does not replace the existing post-chemo pathway. If you have already completed taxane chemotherapy and your PSMA-PET is positive, you may still be eligible under the original approval, subject to other clinical criteria.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.